Vir Biotechnology, Inc. (VIR) Stock Price & Analysis

Vir Biotechnology, Inc. (VIR) fell 2.59% to USD 11.09 as of September 8, 2026 at 14:08 UTC, according to Nexqual real-time market data.

VIR last closed at USD 11.09; the session ranged USD 11–11.27 on volume of 207,267 shares. Market capitalization is —, with a 52-week range of USD 4.75–11.94 (NMS). Source: Nexqual, September 8, 2026 at 14:08 UTC.

Key Statistics (as of September 8, 2026 at 14:08 UTC)

Technical Analysis (VIR)

Nexqual's technical model rates VIR "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of September 8, 2026 at 14:08 UTC.

From Vir Biotechnology, Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)

Key Strengths & Strategy (as disclosed to the SEC)

• We will receive $335 million in upfront and near-term milestone payments, including $240 million in cash, a $75 million equity investment pursuant to a separate Stock Purchase Agreement (the Astellas SPA, described further below), and a near-term $20 million milestone payment upon completion of manufacturing technology transfer, anticipated in the second quarter or third quarter of 2027.
• We use our world-class capabilities in antibody discovery and engineering, coupled with our proprietary AI engine dAIsY ™ system, and the PRO-XTEN ® masking platform, to quickly and effectively discover and optimize potential new medicines.
• Tobevibart was identified using our proprietary antibody discovery platform.
• Our platform has been successfully applied to identify mAbs for multiple pathogens including SARS-CoV-2, HBV, HDV, Ebola virus, and HIV.

Partnerships

• In connection with the 2021 GSK Agreement, we entered into a stock purchase agreement with GGL pursuant to which we issued 1,924,927 shares of our common stock to GGL for an aggregate purchase price of approximately $120.0 million.
• Concurrently with the execution of the Astellas Agreement, we have also entered into the Astellas SPA, pursuant to which Astellas has agreed to purchase 7,239,382 shares of our common stock for an aggregate purchase price of approximately $75 million, subject to customary closing conditions and the closing of the Astellas Agreement.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 14:08 UTC. This page is informational and not investment advice.